Table 1 Patient demographics and baseline characteristics in AFM11-101

Age (y), mean (SD)

56.5 (16.52)

Male, n (%)

10 (62.5)

Diagnosis NHL, n (%)

16 (100)

Time since diagnosis (y), mean (SD)

4.80 (4.35)

Disease status at screening, n (%)

 Stage I

1 (6.3)

 Stage II

1 (6.3)

 Stage III

2 (12.5)

 Stage IV

12 (75)

Previous treatments, n (%)

 At least 1 line of prior systemic therapy

16 (100)

 Chemotherapy alone

15 (93.8)

 Other^a

9 (56.3)

 ASCT

7 (43.8)

 Anti-CD20 therapy

6 (37.5)

 Targeted small molecule kinase

4 (25.0)

 Immunotherapy^b

3 (18.8)

 ≥ 1 prior radiotherapy

5 (31.3)